Physician profile
Timothy Cornnell
NPI 1114913050
$8,834.97
in general payments reported to CMS, 2019-2025
34 companies · $1,426 in 2025
The $1,426 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $310 · 2021: $1,603 · 2022: $1,079 · 2023: $2,167 · 2024: $1,798 · 2025: $1,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,391.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,305.09 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Gilead Sciences, INC. | $636.20 | 2019-2025 | Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $564.48 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Janssen Biotech, INC. | $511.46 | 2019-2025 | Stelara, Tremfya, Simponi |
| Genzyme Corporation | $397.81 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $370.22 | 2021-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $333.82 | 2019-2025 | Entyvio, Gattex |
| Nestle Healthcare Nutrition INC. | $251.00 | 2021-2023 | |
| Celgene Corporation | $250.48 | 2021-2024 | Zeposia |
| Allergan, INC. | $225.54 | 2019 | |
| Medtronic, INC. | $213.57 | 2021-2024 | Interstim |
| Regeneron Healthcare Solutions, INC. | $193.26 | 2023-2025 | Dupixent |
| Daiichi Sankyo INC. | $183.42 | 2020-2025 | Injectafer |
| Pfizer INC. | $179.27 | 2022-2025 | |
| Qol Medical, LLC | $171.87 | 2021-2025 | Sucraid, Sucraid |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $143.05 | 2020-2023 | Ocaliva |
| Janssen Scientific Affairs, LLC | $126.92 | 2023 | Stelara |
| Lilly USA, LLC | $123.40 | 2023-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $112.08 | 2023 | |
| Merck Sharp & Dohme LLC | $95.80 | 2019-2024 | Dificid |
| Ardelyx, INC. | $82.00 | 2022-2025 | Ibsrela |
| Redhill Biopharma INC. | $49.12 | 2021 | |
| Alnylam Pharmaceuticals INC. | $46.44 | 2023-2024 | Givlaari |
| Ferring Pharmaceuticals INC. | $42.55 | 2021-2022 | |
| Echosens North America, INC. | $31.59 | 2019 | |
| Thd America, INC. | $31.26 | 2023-2024 | |
| Intra-Sana Laboratories | $29.89 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $28.15 | 2023-2025 | Voquezna |
| Boston Scientific Corporation | $27.14 | 2019-2021 | |
| Amgen INC. | $21.14 | 2023 | Avsola, Amjevita |
| Madrigal Pharmaceuticals | $18.39 | 2024 | Resmetirom |
| Laborie Medical Technologies Corp. | $17.28 | 2023 | |
| Braintree Laboratories, INC. | $14.96 | 2020 | |
| Endogastric Solutions, INC | $6.32 | 2024 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Cornnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.